The stock price

Quote

In a securities filing PFE said “Under Dr. Bourla’s leadership in 2024, Pfizer successfully executed a year of transformative change and advanced innovation, realigning the R&D organization to help drive progress,”

The market is forward looking and neither analysts or investors share the Pollyanna beliefs of Pfizer regarding AB’s leadership to so called progress
 




The faintest praise you'll ever see for a stock:

Joshua Brown from Ritholtz Wealth Management recently talked about Pfizer Inc (NYSE:pFE) during a program on CNBC. Here is what he said about the stock that is down 7% over the past 12 months:

“This is like the worst stock on earth. It stopped going down, interestingly. It’s not going up like a lot of healthcare stocks did from the start of this year. So I missed out on that rotation by literally owning the worst healthcare stock in the world. But 18 times trailing P/E, 10 times trailing EV to EBITDA. They’ve had huge earnings challenges because they bet the ranch on COVID, and that ship has sailed. They haven’t replaced it yet with a robust enough pipeline for people to start taking their estimates higher. But that’s, I think, how I get bailed out of this thing. I’m flat. I don’t want anyone to feel bad. I have much worse stocks. But just the way that this company is being treated by investors right now, it’s like a ghost. But I think ultimately this is the type of stock where when it does turn, it’ll move too fast to catch it. And so that’s what I’m positioned for.”
Click to expand...
This is what happens when you invest on hope
 


PFE is down like many other major stocks and all Indexes. HOWEVER for the past week:

PFE minus 11.44
Dow Jones minus 10.37
NASDAQ minus 10.87
NYSE minus 11.02
Is this the "leadership" we keep talking about? Leading to the bottom
 


Motley Fool now says PFE is worth considering. Price has dropped enough to make it worth a gamble, P/E ratio is half the healthcare avg. PFE has 100+ compounds in development across many categories, finally has rationalized revenue expectations from covid. Compared to most pharma, PFE has multiple operating production sites in the US which could allow PFE an advantage if tariffs are applied to drugs or drug components.

It seems like a reasonable argument to buy but the PFE history of poor integration of acquisitions, boneheaded leadership decisions/ forecasting and lack of business focus remain significant drags on investor sentiment. With other options beaten down by policy turmoil, why choose PFE?
 








Top Bottom
Back
Quote